Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Growth in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 44,900 shares, a growth of 271.1% from the January 15th total of 12,100 shares. Based on an average trading volume of 28,300 shares, the short-interest ratio is currently 1.6 days. Approximately 0.9% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a research note on Wednesday, January 15th.

Hedge Funds Weigh In On Aprea Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Landscape Capital Management L.L.C. bought a new position in Aprea Therapeutics during the fourth quarter worth $116,000. LPL Financial LLC bought a new position in Aprea Therapeutics during the fourth quarter worth $53,000. Finally, Dimensional Fund Advisors LP bought a new position in Aprea Therapeutics during the second quarter worth $45,000. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Stock Up 3.6 %

Shares of NASDAQ APRE opened at $3.43 on Thursday. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $8.85. The firm has a fifty day simple moving average of $3.62 and a 200 day simple moving average of $3.44. The company has a market capitalization of $18.62 million, a PE ratio of -1.22 and a beta of 0.76.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.